The Clorox Company, based in Oakland, California, is an American global manufacturer and marketer of consumer and professional products.
| Revenue (TTM) | $6.72B |
| Gross Profit (TTM) | $2.84B |
| EBITDA | $1.14B |
| Operating Margin | 12.90% |
| Return on Equity | 163.80% |
| Return on Assets | 8.32% |
| Revenue/Share (TTM) | $55.18 |
| Book Value | $0.74 |
| Price-to-Book | 117.10 |
| Price-to-Sales (TTM) | 1.57 |
| EV/Revenue | 2.311 |
| EV/EBITDA | 13.29 |
| Quarterly Earnings Growth (YoY) | -50.10% |
| Quarterly Revenue Growth (YoY) | -2.00% |
| Shares Outstanding | $120.94M |
| Float | $120.49M |
| % Insiders | 0.69% |
| % Institutions | 88.34% |
Volatility is currently contracting
Six stocks are flashing high yields that look like income bargains, but a closer look at their payout ratios tells a very different story about which ones can actually keep the checks coming.
OAKLAND, Calif., Oct. 12, 2026 /PRNewswire/ -- The Clorox Company (NYSE: CLX) will issue its first-quarter fiscal year 2027 results on November 2, 2026.
CL's fundamentals are supported by global diversification, emerging-market growth and Hill's strength, while CLX leans on recovery and GOJO.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
CLX's innovation, GOJO acquisition and digital transformation are strengthening its health and hygiene portfolio while supporting long-term growth.
Investors need to pay close attention to CLX stock based on the movements in the options market lately.
The Clorox Company (CLX) trades at a depressed 14x forward P/E and offers a 6% dividend yield, but faces ongoing macro and execution headwinds. Despite a brighter FY27 outlook, CLX's near-term organic growth and margin expansion remain challenged by inflation, weak volumes, and integration risks from the GOJO acquisition. I maintain a hold rating, as a turnaround appears at least 12–24 months away, with upside hinging on cost synergies, successful integration, and margin recovery.
The new B2B-focused business, created through the combination of CloroxPro and GOJO, Makers of Purell, brings professional and healthcare customers unparalleled access to the most trusted health and hygiene solutions in the industry. OAKLAND, Calif.
Clorox has raised its dividend for decades, but a cratering stock price, a payout ratio management calls elevated, and a debt load that ballooned after two major deals raise a pointed question about whether that streak survives fiscal 2027.
The Clorox Company's stock price has dropped by roughly 21% in just 1 month. I'm downgrading CLX to a Sell due to persistent financial weakness and lack of turnaround catalysts. CLX reported a 13% organic sales drop and gross margin contraction of 520 basis points, signaling ongoing operational challenges.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CLX and any ticker you trade — then tracks every position and per-strategy win rate.
